# IAP7 Rec'd PCT/PTO 13 APR 2006

Form PTO (REV 5-93)		ATTORNEY'S DOCKET NUMBER VB60528					
7	TRANSMITTAL LETTER T DESIGNATED / ELECTE CONCERNING A FILING	u.s. application no. (Ifknown, see 37 C.F.R. 1.5) Unknown 5 7 5 8 3 8					
	ATIONAL APPLICATION NO. EP2004/011620	INTERNATIONAL FILING DATE 11 October 2004	PRIORITY DATE CLAIMED 13 October 2003				
TITLE OF INVENTION  VACCINE COMPOSITIONS COMPRISING AN INTERLEUKIN 18 AND SAPONIN ADJUVANT SYSTEM							
APPLICANT(S) FOR DO/EO/US  Claudine Elvire Marie BRUCK, Catherine Marie Ghislaine GERARD and Zdenka Ludmila JONAK							
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:							
<ol> <li>[x] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>[] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>[x] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>[x] The US has been elected (Article 31).</li> </ol>							
5. [x]	<ul> <li>[X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))</li> <li>a. [] is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. [X] has been transmitted by the International Bureau.</li> <li>c. [] is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul>						
7. []							
9. []	A translation of the amendments to the claims under PCT Article 19 (35 U.S. C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).  a. [] was submitted as part of the international application under Rule 4.17(iv).  A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).						
11. [x]	<ul> <li>11. to 16. below concern other document(s) or information included:</li> <li>[X] An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449.</li> <li>[An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.</li> </ul>						
14. [] 15. []	A FIRST preliminary amendment.  (Add claim to priority via Preliminary Amendment for US originating cases only)  A SECOND or SUBSEQUENT preliminary amendment.  A substitute specification.  Power of attorney.						
18. [x]	An Abstract on a separate sheet of paper.  Copy of Form PCT/ISA/210.  Other items or information.						

JAP20 Rec'd PCT/FTO 13 APR 2006

US APPLICATION I	NO. (if known see 37 CFR 1.5	L APPLICATION NO.	ATTORNEYS DOCKET NO.			
Unknown∩.	575838		PCT/EP2004/011620		VB60528	
20. [X] The fo	llowing fees are submitt	CALCULATION	PTO USE ONLY			
Basic	National Fee (37 C.F.)					
■ Basic	Filing Fee		\$300.00	\$300.00		
	nation Fee					
	nal Preliminary Examination					
satisfy prov	visions of PCTArtlice33(1)	\$200.00				
			\$200.00			
■ Search					ĺ	
	37 CFR 1.445(a)(2) has be	=				
1	-	=	\$100.00	\$400.00		
			ice\$400.00			
*All other situ	ations					
			E CALCULATIONS =	\$900.00		
	0.00 for furnishing the o			\$0.00		
	earliest claimed priority					
Claims		Number Extra	Rate			
Total claims	32 - 20 =	12	12 x \$50.00	\$600.00		
Independent	6 - 3 =	3	3 x \$200.00	\$600.00		
claims			. \$2.0.00	Φ0.00		
Multiple depende	ent claims (if applicable)		+ \$360.00 VE CALCULATIONS =	\$0.00		
,		\$2,100.00				
	pplication size fee-for e	\$0.00				
that exceed 100 s						
thereof.   SUBTOTAL = \$2,100.00						
		\$2,100.00				
	\$130.00 for furnishing					
20 30 mon	ths from the earliest clai	<b>#2.400.00</b>				
		\$2,100.00				
				Amount to be	\$	
		refunded				
				charged	\$	

	П	A check in the amount of \$	to cover the above fees is enclosed
a.		A check in the amount of \$	to cover the above lees is enclosed

- b.  $\boxtimes$  Please charge my Deposit Account No. 19-2570 in the amount of \$2,100.00 to cover the above fees.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

**SEND ALL CORRESPONDENCE TO:** 

**GLAXOSMITHKLINE** 

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5009

Facsimile (610) 270-5090

SIGNATURE

Elizabeth J. Hecht

NAME

41,824

REGISTRATION NO.

10/5/5000

### IAP20 Rec'd PCT/FTO 13 APR 2005

**PATENT** 

#### ATTORNEY'S DOCKET NUMBER **VB60528**

## TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE (DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO.

INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

PCT/EP2004/011620

11 October 2004

13 October 2003

TITLE OF INVENTION

VACCINE COMPOSITIONS COMPRISING AN INTERLEUKIN 18 AND SAPONIN ADJUVANT SYSTEM

APPLICANT(S) FOR DO/US

Claudine Elvire Marie BRUCK, Catherine Marie Ghislaine GERARD and Zdenka Ludmila JONAK

Commissioner for Patents

Mail Stop: PCT P.O. Box 1450

Alexandria, VA 22313-1450 ATTENTION: DO/US

#### **CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date <u>13 April 2006</u> in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number <u>EV710806016 US</u> addressed to the:

MOMANCIUS KI

Commissioner for Patents, Mail Stop: PCT, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper)

(Signature of person mailing paper)